{"analyses":[{"groupDescription":"bALP changes from baseline to cycle 1","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.002","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"b-ALP changes from baseline to cycle 4","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"t-test, 2 sided"},{"groupDescription":"DKK-1 changes from baseline to cycle 1","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.005","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"DKK-1 changes from baseline to cycle 4","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.11","value":"21.87"}]}],"title":"bALP on baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.89","value":"23.2"}]}],"title":"bALP after cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.02","value":"1.33"}]}],"title":"bALP changes from baseline to cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.12","value":"28.75"}]}],"title":"bALP after cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.20","value":"6.88"}]}],"title":"bALP changes from baseline to cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"159.5","value":"4765"}]}],"title":"DKK-1 on baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"135.2","value":"2653"}]}],"title":"DKK-1 aftercycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"135.2","value":"2653"}]}],"title":"DKK-1 changes from baseline to cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"128.2","value":"1589"}]}],"title":"DKK-1 after cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"123.8","value":"3176"}]}],"title":"DKK-1 changes from baseline to cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The bone formation marker- bone alkaline phosphatase(bALP) and osteoblast inhibitor- Dickkopf-1(DKK-1）are measured on serum samples by ELISA methodology at baseline, on day 28 of cycles 1,4, and after 4, 6, 12 and 18 months of follow-up or until start of alternative multiple myeloma(MM) treatment, if earlier.","dispersionType":"Standard Deviation","groups":[{"description":"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\n\nPAD Followed by ASCT: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)\n\nDrug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)\n\nDrug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.","id":"OG000","title":"PAD Followed by ASCT"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to Cycle 4 with 28 days per cycle","title":"Bone Formation Markers Measurement","type":"PRIMARY","unitOfMeasure":"U/L"}